lobbying_activities: 2961049

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2961049	0edef954-e4af-4d10-b6bf-1c20fc14129f	Q1	EMERGENT STRATEGIES	401104778	GENBIOPRO, INC.	2023	first_quarter	PHA	FDA Approval of generic mifepristone and related Risk Evaluation Mitigation Strategies (REMS).	Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE	35000		0	0	2023-04-17T11:17:03-04:00